Literature DB >> 18281489

Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers.

Yan Wang1, Dongping Liu, Pingping Chen, H Phillip Koeffler, Xiangjun Tong, Dong Xie.   

Abstract

IFN-gamma is an antitumor cytokine that inhibits cell proliferation and induces apoptosis after engagement with the IFN-gamma receptors (IFNGR) expressed on target cells, whereas IFN regulatory factor 2 (IRF-2) is able to block the effects of IFN-gamma by repressing transcription of IFN-gamma-induced genes. Thus far, few studies have explored the influences of IFN-gamma on human esophageal cancer cells. In the present study, therefore, we investigated in detail the functions of IFN-gamma in esophageal cancer cells. The results in clinical samples of human esophageal cancers showed that the level of IFN-gamma was increased in tumor tissues and positively correlated with tumor progression and IRF-2 expression, whereas the level of IFNGR1 was decreased and negatively correlated with tumor progression and IRF-2 expression. Consistently, in vitro experiments showed that low concentration of IFN-gamma induced the expression of IRF-2 with potential promotion of cell growth, and moreover, IRF-2 was able to suppress IFNGR1 transcription in human esophageal cancer cells by binding a specific motif in IFNGR1 promoter, which lowered the sensitivity of esophageal cancer cells to IFN-gamma. Taken together, our results disclosed a new IRF-2-mediated inhibitory mechanism for IFN-gamma-induced pathway in esophageal cancer cells: IFN-gamma induced IRF-2 up-regulation, then up-regulated IRF-2 decreased endogenous IFNGR1 level, and finally, the loss of IFNGR1 turned to enhance the resistance of esophageal cancer cells to IFN-gamma. Accordingly, the results implied that IRF-2 might act as a mediator for the functions of IFN-gamma and IFNGR1 in human esophageal cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281489     DOI: 10.1158/0008-5472.CAN-07-5021

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.

Authors:  Nafiseh Pakravan; Zuhair Mohammad Hassan
Journal:  Cell Stress Chaperones       Date:  2011-02-26       Impact factor: 3.667

2.  IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.

Authors:  Lei Cui; Yuezhen Deng; Yefei Rong; Wenhui Lou; Zhengfa Mao; Yuanyuan Feng; Dong Xie; Dayong Jin
Journal:  Tumour Biol       Date:  2011-11-26

3.  Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  Int J Biochem Cell Biol       Date:  2010-04-13       Impact factor: 5.085

4.  Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21.

Authors:  Hadiseh Samiei; Bizhan Sadighi-Moghaddam; Saeed Mohammadi; Abdolsamad Gharavi; Sara Abdolmaleki; Ayyoob Khosravi; Parviz Kokhaei; Hadi Bazzazi; Ali Memarian
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

5.  Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.

Authors:  Giang Huong Nguyen; Aaron J Schetter; David B Chou; Elise D Bowman; Ronghua Zhao; Jason E Hawkes; Ewy A Mathé; Kensuke Kumamoto; Yiqiang Zhao; Anuradha Budhu; Nobutoshi Hagiwara; Xin Wei Wang; Masao Miyashita; Alan G Casson; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2010-10-14       Impact factor: 12.531

Review 6.  Research advances at the Institute for Nutritional Sciences at Shanghai, China.

Authors:  Yan Chen; Xu Lin; Yong Liu; Dong Xie; Jing Fang; Yingying Le; Zunji Ke; Qiwei Zhai; Hui Wang; Feifan Guo; Fudi Wang; Yi Liu
Journal:  Adv Nutr       Date:  2011-09-06       Impact factor: 8.701

7.  Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

Authors:  Cristina Segovia; Edurne San José-Enériz; Ester Munera-Maravilla; Mónica Martínez-Fernández; Leire Garate; Estíbaliz Miranda; Amaia Vilas-Zornoza; Iris Lodewijk; Carolina Rubio; Carmen Segrelles; Luis Vitores Valcárcel; Obdulia Rabal; Noelia Casares; Alejandra Bernardini; Cristian Suarez-Cabrera; Fernando F López-Calderón; Puri Fortes; José A Casado; Marta Dueñas; Felipe Villacampa; Juan José Lasarte; Félix Guerrero-Ramos; Guillermo de Velasco; Julen Oyarzabal; Daniel Castellano; Xabier Agirre; Felipe Prósper; Jesús M Paramio
Journal:  Nat Med       Date:  2019-07-03       Impact factor: 53.440

8.  Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers.

Authors:  Jana Ivanidze; Reinhard Hoffmann; Hanns Lochmüller; Andrew G Engel; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Am J Pathol       Date:  2011-09       Impact factor: 4.307

9.  Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival.

Authors:  Shun Lu; Barbara Pardini; Bowang Cheng; Alessio Naccarati; Stefanie Huhn; Veronika Vymetalkova; Ludmila Vodickova; Thomas Buchler; Kari Hemminki; Pavel Vodicka; Asta Försti
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

10.  miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer.

Authors:  Mingxin Zhang; Lingmin Zhang; Manli Cui; Wenguang Ye; Pengjiang Zhang; Suna Zhou; Jingjie Wang
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.